ArticleJournal of comparative effectiveness research2023

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer.

Jing Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.